Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Replay: Refining the Hepatic Risk Interpretation in APOB Loss-Of-Function.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: May 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Treating statin-intolerant patients.

Marcello Arca1, Giovanni Pigna

  • 1Atherosclerosis Unit, Department of Internal Medicine and Allied Medical Specialities, Sapienza University of Rome, Rome, Italy.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|July 23, 2011
PubMed
Summary
This summary is machine-generated.

Statin intolerance, often due to muscle or liver issues, affects adherence. Managing these side effects is key to maintaining cardiovascular benefits for patients on statin therapy.

Keywords:
aminotransferase levelsatorvastatinmyopathyrosuvastatinstatin therapy

Related Experiment Videos

Last Updated: May 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Statins are primary agents for cardiovascular event reduction.
  • Statin intolerance, primarily muscular and hepatic adverse events, impacts patient adherence and therapeutic outcomes.
  • Effective management of statin-associated side effects is crucial for sustained cardiovascular protection.

Purpose of the Study:

  • To review clinical aspects and proposed mechanisms of common statin-associated side effects.
  • To examine current strategies for managing patients with statin intolerance.
  • To evaluate the efficacy and cholesterol-lowering potency of various management approaches.

Main Methods:

  • Review of clinical literature on statin-associated muscular and hepatic side effects.
  • Analysis of proposed mechanisms underlying statin intolerance.
  • Evaluation of management strategies including dosage reduction, statin switching, alternate dosing, and non-statin therapies.

Main Results:

  • Muscular symptoms and elevated aminotransferases are the predominant causes of statin intolerance, accounting for two-thirds of adverse events.
  • Management options include dose adjustment, switching statins, alternative dosing schedules, or employing non-statin medications.
  • The clinical utility and comparative effectiveness of these strategies require further investigation.

Conclusions:

  • Clinicians must enhance their understanding of statin side effects and management protocols.
  • Personalized patient assessment is essential when implementing strategies for statin intolerance.
  • Further research is needed to establish the long-term cardiovascular benefits of managing statin intolerance.